Florida Health Daily
SEE OTHER BRANDS

Your best source on healthcare and wellness news from Florida

Florida Health Daily: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.

Press releases published on May 19, 2025

Living with disability? Registration is open for no-cost Summer Adventure program

Living with disability? Registration is open for no-cost Summer Adventure program

East St. Louis, Illinois, May 19, 2025 (GLOBE NEWSWIRE) -- For many families, summer means scrambling to find caregiving arrangements. For families living with disability, the search for summer help is even harder.   Thankfully, the disability ministry …

Thousands of Retailers Across the Country Partner with Muscular Dystrophy Association to Send Kids to Summer Camp at No Cost to Families

Thousands of Retailers Across the Country Partner with Muscular Dystrophy Association to Send Kids to Summer Camp at No Cost to Families

New York, May 19, 2025 (GLOBE NEWSWIRE) -- This summer, shoppers across the U.S. have the chance to make an extraordinary difference in the lives of kids and young adults living with neuromuscular diseases, by participating in the pinup and roundup …

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals

Following the formal safety review of Cohort 1, no safety or tolerability issues were observed, allowing the company to move forward with Cohort 2. The company plans on releasing more detailed results from Phase 1 later in 2025 following completion of …

Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer

Arbor Biotechnologies Appoints Don Haut, Ph.D., as Chief Business Officer

CAMBRIDGE, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Arbor Biotechnologies, Inc., a biotechnology company discovering and developing the next generation of genetic medicines, today announced the appointment of Don Haut, Ph.D., as Chief Business Officer. In …

MEDIROM Healthcare Technologies Inc. to Host Webcast on May 21, 2025 at 8:30 AM ET to Discuss 2024 Financial Results

MEDIROM Healthcare Technologies Inc. to Host Webcast on May 21, 2025 at 8:30 AM ET to Discuss 2024 Financial Results

TOKYO, May 19, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in Japan (the “Company” or “MEDIROM”) today announced that it will host a webcast to review the Company’s financial results …

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

Prime Medicine Announces Strategic Restructuring to Focus on Opportunities in Large Genetic Liver Diseases, Cystic Fibrosis, and Partnered Programs Alongside CEO Leadership Transition

-- Initial positive data from Phase 1/2 clinical trial of PM359 in CGD provide clinical proof-of-concept for Prime Editing as a transformative gene editing technology -- -- On-track to file IND and/or CTA for Wilson’s Disease and AATD programs in 1H 2026 …

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

Phase II Data in Treatment-Naïve Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Demonstrates Best-in-Class Efficacy as Monotherapy

--- Ruxoprubart (NM8074) met all clinical endpoints, offering a safe, differentiated treatment for Paroxysmal Nocturnal Hemoglobinuria (PNH). Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare hematological (Blood) disorder. Regulatory approval for the …

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease

-- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity by Day 15 and 66% by Day 30, well above levels …

Lifeward Names Mark Grant as New CEO

Lifeward Names Mark Grant as New CEO

MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (Nasdaq: LFWD) (“Lifeward” or the “Company”), a global leader in innovative medical technology to transform the lives of people with physical limitations or …

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

Intelligent Bio Solutions Showcases Rapid, Non-Invasive Drug Testing Capabilities in Remote Queensland Workforce Deployment

NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced the successful completion of a …

Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161

Juvena Therapeutics Announces Initiation of First-in-Human Clinical Trial of JUV-161

JUV-161 is a first-in-class muscle regenerating biologic that will address myopathies starting with Myotonic Dystrophy Type 1 JUV-161 was discovered using Juvena’s proprietary JuvNET platform, an AI and stem cell secretome-based drug discovery and …

FOXO TECHNOLOGIES INC.’S CRITICAL ACCESS HOSPITAL ANNOUNCES EXPANSION OF SERVICES TO INCLUDE WOUND CARE

FOXO TECHNOLOGIES INC.’S CRITICAL ACCESS HOSPITAL ANNOUNCES EXPANSION OF SERVICES TO INCLUDE WOUND CARE

WEST PALM BEACH, FLORIDA, May 19, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“FOXO” or the “Company”) today announced that its critical access hospital, Big South Fork Medical Center in Oneida, Tennessee, is expanding its …

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

TAMPA, FL, May 19, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. NASDAQ: SCNX), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through developing, …

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical …

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX “Radiopharm”), a developer of a world-class …

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the …

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein --Avoided broad JAK-mediated immune suppression --Data presented at the American Thoracic …

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its …

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service